Jonathan S Cebon

Loading... 2 0 20 0 false
Credit Name
Jonathan S Cebon
Full Name
Cebon, Jonathan S
 
 
Loading... 3 0 20 0 false

Publications

Refined By:
Subject:  Male

Results 1-20 of 28 (Search time: 0.021 seconds).

Publication YearTitleAuthor(s)
16-Oct-2014Combined BRAF (Dabrafenib) and MEK inhibition (Trametinib) in patients with BRAFV600-mutant melanoma experiencing progression with single-agent BRAF inhibitor.Johnson, Douglas B; Flaherty, Keith T; Weber, Jeffrey S; Infante, Jeffrey R; Kim, Kevin B; Kefford, Richard F; Hamid, Omid; Schuchter, Lynn; Cebon, Jonathan S ; Sharfman, William H; McWilliams, Robert R; Sznol, Mario; Lawrence, Donald P; Gibney, Geoffrey T; Burris, Howard A; Falchook, Gerald S; Algazi, Alain; Lewis, Karl; Long, Georgina V; Patel, Kiran; Ibrahim, Nageatte; Sun, Peng; Little, Shonda; Cunningham, Elizabeth; Sosman, Jeffrey A; Daud, Adil; Gonzalez, Rene
21-Apr-2014A single-centre experience of patients with metastatic melanoma enrolled in a dabrafenib named patient programme.Lau, David K ; Andrews, Miles C; Turner, Natalie; Azad, Arun A; Davis, Ian D; Cebon, Jonathan S 
34-Nov-2013BRAF inhibitor-driven tumor proliferation in a KRAS-mutated colon carcinoma is not overcome by MEK1/2 inhibition.Andrews, Miles C; Behren, Andreas; Chionh, Fiona; Mariadason, John M ; Vella, Laura J; Do, Hongdo; Dobrovic, Alexander ; Tebbutt, Niall C ; Cebon, Jonathan S 
411-Oct-2013Intratumoral genetic heterogeneity in metastatic melanoma is accompanied by variation in malignant behaviors.Anaka, Matthew; Hudson, Christopher; Lo, Pu-Han; Do, Hongdo; Caballero, Otavia L; Davis, Ian D; Dobrovic, Alexander ; Cebon, Jonathan S ; Behren, Andreas
523-Jul-2013The role of Cancer-Testis antigens as predictive and prognostic markers in non-small cell lung cancer.John, Thomas ; Starmans, Maud H W; Chen, Yao-Tseng; Russell, Prudence A; Barnett, Stephen A ; White, Shane C; Mitchell, Paul L R ; Walkiewicz, Marzena; Azad, Arun A; Lambin, Philippe; Tsao, Ming-Sound; Deb, Siddhartha; Altorki, Nasser; Wright, Gavin; Knight, Simon R ; Boutros, Paul C; Cebon, Jonathan S 
611-Apr-2013The Ludwig institute for cancer research Melbourne melanoma cell line panel.Behren, Andreas; Anaka, Matthew; Lo, Pu-Han; Vella, Laura J; Davis, Ian D; Catimel, Jenny; Cardwell, Tracy; Gedye, Craig; Hudson, Christopher; Stan, Rodica; Cebon, Jonathan S 
727-Feb-2013Fine-mapping naturally occurring NY-ESO-1 antibody epitopes in melanoma patients' sera using short overlapping peptides and full-length recombinant protein.Komatsu, Nobukazu; Jackson, Heather M; Chan, Kok-fei; Oveissi, Sara; Cebon, Jonathan S ; Itoh, Kyogo; Chen, Weisan
81-Feb-2012Stem cell media culture of melanoma results in the induction of a nonrepresentative neural expression profile.Anaka, Matthew; Freyer, Claudia; Gedye, Craig; Caballero, Otavia; Davis, Ian D; Behren, Andreas; Cebon, Jonathan S 
923-Jun-2011Immunoediting and persistence of antigen-specific immunity in patients who have previously been vaccinated with NY-ESO-1 protein formulated in ISCOMATRIX™.Nicholaou, Theo; Chen, Weisan; Davis, Ian D; Jackson, Heather M; Dimopoulos, Nektaria; Barrow, Catherine; Browning, Judy; Macgregor, Duncan; Williams, David; Hopkins, Wendie; Maraskovsky, Eugene; Venhaus, Ralph; Pan, Linda; Hoffman, Eric W; Old, Lloyd J; Cebon, Jonathan S 
104-Nov-2010Cancer-testis antigen expression in primary cutaneous melanoma has independent prognostic value comparable to that of Breslow thickness, ulceration and mitotic rate.Svobodová, Suzanne; Browning, Judy; MacGregor, Duncan; Pollara, Gabriele; Scolyer, Richard A; Murali, Rajmohan; Thompson, John F; Deb, Siddhartha; Azad, Arun A; Davis, Ian D; Cebon, Jonathan S 
1110-Mar-2009Regulatory T-cell-mediated attenuation of T-cell responses to the NY-ESO-1 ISCOMATRIX vaccine in patients with advanced malignant melanoma.Nicholaou, Theo; Ebert, Lisa M; Davis, Ian D; McArthur, Grant A; Jackson, Heather M; Dimopoulos, Nektaria; Tan, Bee; Maraskovsky, Eugene; Miloradovic, Lena; Hopkins, Wendie; Pan, Linda; Venhaus, Ralph; Hoffman, Eric W; Chen, Weisan; Cebon, Jonathan S 
1210-Mar-2009Clinical and biological efficacy of recombinant human interleukin-21 in patients with stage IV malignant melanoma without prior treatment: a phase IIa trial.Davis, Ian D; Brady, Ben; Kefford, Richard F; Millward, Michael; Cebon, Jonathan S ; Skrumsager, Birte K; Mouritzen, Ulrik; Hansen, Lasse Tengbjerg; Skak, Kresten; Lundsgaard, Dorthe; Frederiksen, Klaus Stensgaard; Kristjansen, Paul E G; McArthur, Grant A
1317-Feb-2009Cancer/testis antigens can be immunological targets in clonogenic CD133+ melanoma cells.Gedye, Craig; Quirk, Juliet; Browning, Judy; Svobodová, Suzanne; John, Thomas ; Sluka, Pavel; Dunbar, P Rod; Corbeil, Denis; Cebon, Jonathan S ; Davis, Ian D
1415-Aug-2008Predicting clinical outcome through molecular profiling in stage III melanoma.John, Thomas ; Black, Michael A; Toro, Tumi T; Leader, Debbie; Gedye, Craig A; Davis, Ian D; Guilford, Parry J; Cebon, Jonathan S 
1515-Apr-2008The regulatory T cell-associated transcription factor FoxP3 is expressed by tumor cells.Ebert, Lisa M; Tan, Bee Shin; Browning, Judy; Svobodova, Suzanne; Russell, Sarah E; Kirkpatrick, Naomi; Gedye, Craig; Moss, Denis; Ng, Sweet Ping ; MacGregor, Duncan; Davis, Ian D; Cebon, Jonathan S ; Chen, Weisan
1615-Jun-2007An open-label, two-arm, phase I trial of recombinant human interleukin-21 in patients with metastatic melanoma.Davis, Ian D; Skrumsager, Birte K; Cebon, Jonathan S ; Nicholaou, Theo; Barlow, John W; Moller, Niels Peter Hundahl; Skak, Kresten; Lundsgaard, Dorthe; Frederiksen, Klaus Stensgaard; Thygesen, Peter; McArthur, Grant A
1710-Sep-2006Blood dendritic cells generated with Flt3 ligand and CD40 ligand prime CD8+ T cells efficiently in cancer patients.Davis, Ian D; Chen, Qiyuan; Morris, Leone; Quirk, Juliet; Stanley, Maureen; Tavarnesi, Maria L; Parente, Phillip; Cavicchiolo, Tina; Hopkins, Wendie; Jackson, Heather M; Dimopoulos, Nektaria; Tai, Tsin Yee; MacGregor, Duncan; Browning, Judy; Svobodova, Suzanne; Caron, Dania; Maraskovsky, Eugene; Old, Lloyd J; Chen, Weisan; Cebon, Jonathan S 
181-Aug-2006Desmoplastic melanoma: comparison of expression of differentiation antigens and cancer testis antigens.Lim, Elgene; Browning, Judy; MacGregor, Duncan; Davis, Ian D; Cebon, Jonathan S 
1915-May-2006Striking immunodominance hierarchy of naturally occurring CD8+ and CD4+ T cell responses to tumor antigen NY-ESO-1.Jackson, Heather M; Dimopoulos, Nektaria; Mifsud, Nicole A; Tai, Tsin Yee; Chen, Qiyuan; Svobodova, Suzanne; Browning, Judy; Luescher, Immanuel F; Stockert, Lisa; Old, Lloyd J; Davis, Ian D; Cebon, Jonathan S ; Chen, Weisan
2019-Nov-2005A phase 1 and pharmacokinetic study of gemcitabine and oxaliplatin in patients with solid tumors.Gan, Hui K ; Mitchell, Paul L R ; Galettis, Peter; Davis, Ian D; Cebon, Jonathan S ; de Souza, Paul; Links, Matthew